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Use of Hemagglutinin Stem 
Probes Demonstrate Prevalence of 
Broadly Reactive Group 1 Influenza 
Antibodies in Human Sera
Hadi M. Yassine  1, Patrick M. McTamney2, Jeffery C. Boyington3, Tracy J. Ruckwardt3, 
Michelle C. Crank3, Maria K. Smatti1, Julie E. Ledgerwood3 & Barney S. Graham3
A better understanding of the seroprevalence and specificity of influenza HA stem-directed broadly 
neutralizing antibodies (bNAbs) in the human population could significantly inform influenza vaccine 
design efforts. Here, we utilized probes comprising headless, HA stabilized stem (SS) to determine the 
prevalence, binding and neutralization breadth of antibodies directed to HA stem-epitope in a cross-
sectional analysis of the general population. Five group-1 HA SS probes, representing five subtypes, 
were chosen for this analyses. Eighty-four percent of samples analyzed had specific reactivity to at least 
one probe, with approximately 60% of the samples reactive to H1 probes, and up to 45% reactive to 
each of the non-circulating subtypes. Thirty percent of analyzed sera had cross-reactivity to at least four 
of five probes and this reactivity could be blocked by competing with F10 bNAb. Binding cross-reactivity 
in sera samples significantly correlated with frequency of H1+H5+ cross-reactive B cells. Interestingly, 
only 33% of the cross-reactive sera neutralized both H1N1 and H5N1 pseudoviruses. Cross-reactive and 
neutralizing antibodies were more prevalent in individuals >50 years of age. Our data demonstrate 
the need to use multiple HA-stem probes to assess for broadly reactive antibodies. Further, a universal 
vaccine could be designed to boost pre-existing B-cells expressing stem-directed bNAbs.
Annual influenza epidemics affect up to 15% of the world population and cause about 500,000 annual deaths globally. 
Influenza viruses also periodically cause pandemics, the most recent being in 2009 caused by swine-origin H1N1 
virus1. The antibody response to current influenza vaccines primarily target the head region of the hemagglutinin 
(HA) glycoprotein, which is subject to constant antigenic drift, necessitating annual updates of influenza vaccines2.
Antibodies with broad specificity have been isolated from humans, including those that bind conserved 
epitopes within the stem region of HA3–7. HA stem-specific antibodies can have cross-subtype specificity within 
groups (e.g. CR6261- and F10-like for group 13 or CR8020 for group 27) or cross-group specificity (e.g. FI6, 
CT149 and CR91145,6). Those that target group 1 viruses have been frequently isolated from human subjects 
vaccinated or infected with influenza virus8–10. Interestingly, more than two-thirds of such antibodies are derived 
from the heavy chain VH1-69 gene family, which requires little maturation to achieve broad reactivity11.
The ability to elicit broadly cross-reactive antibodies against the conserved stem of HA could be the basis for an 
influenza vaccine capable of providing protection against various antigenically distinct or drifted influenza strains2. 
In principle, an HA stem-targeting, broad specificity influenza vaccine would not require annual updates, and would 
induce near universal immunity against diverse influenza viruses. For example, it has been shown that vaccination 
with H1-based HA-stabilized stem (SS) nanoparticles, that have the variable HA head region removed, elicit broadly 
cross-reactive antibodies and provides protection in mice and ferrets against lethal heterosubtypic H5N1 influenza 
virus challenge despite the absence of detectable H5N1 neutralizing activity in vitro. Further, passive transfer of 
immunoglobulin from H1 HA SS nanoparticles–immunized mice to naive mice resulted in full protection from 
lethal H5N1 challenge, indicating that HA stem–specific antibodies protect against diverse group 1 influenza subtypes 
in animal models12. Similar vaccination strategies have been reported against group 2 influenza A subtypes as well13.
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Accordingly, reliable methods to detect and assay for broadly reactive stem-specific antibodies will be needed 
to determine their prevalence in the human population, and also to assess the efficacy of next-generation influ-
enza vaccines. Although previous studies have interrogated the prevalence of broadly-reactive stem-directed 
antibodies in humans using various methods including competition assays, chimeric HA, or phage display meth-
ods14–20, none of these studies used structurally-defined stem-only probes to measure binding and stem-specific 
neutralizing activity in human sera. Here, we present a new set of structurally-defined12 stabilized-stem probes 
(seasonal and pandemic H1, H2, H5, and H9) to determine the prevalence, frequency, breadth and specificity 
of broadly reactive antibodies in human sera. Analysis of 202 human sera samples revealed a wide prevalence of 
broadly-reactive antibodies to multiple group-1 HA subtypes.
Materials and Methods
Molecular Cloning and Expression. The genes encoding wild-type HA and NA proteins of H1 NC99 (A/
New Caledonia/30/1999 (H1N1)), H1 CA 09 (A/California/4/2009 (H1N1)), H2 SING 57 (A/Singapore/1/57 
(H2N2)), H5 IND 05 (A/Indonesia/05/05 (H5N1)), and H9 HK 99 (A/Hong Kong/1074/99 (H9N2)), H1 stabi-
lized stem (SS) H1 NC 99 SS, HIV gp120 control protein, and monoclonal Antibodies CR6261, CR8020, FI6v3, 
and F10 were synthesized21. The remaining HA SS probes were constructed by overlapping PCR. Genes encoding 
these proteins were cloned into a CMVR plasmid backbone for mammalian cell expression21,22. Δstem mutant 
probe with two point mutations, Ile45Arg/Thr49Arg (Arg point mutations in HA2; H3 numbering), which pre-
vent binding of bNAb like CR6261 or F10 at the conserved H1 stem epitope were generated using site directed 
mutagenesis (QuikChange II Site-Directed Mutagenesis Kit; Agilent Technologies, CA, USA). Plasmids encod-
ing these proteins were transfected into 293 F cells (a human embryonic kidney cell line) and supernatants were 
harvested 72–96 hrs after transfection. HA trimers and stabilized stem proteins were purified as previously 
described21,23. IgG Antibodies were purified using a Protein G affinity column (GE Healthcare) as described by 
the manufacturer.
Characterization of HA stabilized stem. FPLC purified HA SS proteins (Supplementary Fig. 1) were 
characterized by ELISA using human monoclonal Antibodies CR6261, CR8020 and FI6v36,12,24. H1 HA NC99 
and HIV gp120 proteins served as positive and negative controls, respectively. Ab binding was detected by 
peroxidase-conjugated goat anti-human IgG (Rockland Immunochemicals Inc., PA, USA). Dose-response curve 
was plotted using absorbance reading at Y-axis and antibody dilutions on X-axis. Endpoint dilutions were deter-
mined from non-linear fit dose-response curves using a detection limit of four-fold (4 X) above background 
absorbance (washing buffer alone)12. The HA NC 99 SS was further characterized by ELISA and pseudotype neu-
tralization competition assays. Presence or absence of the stem epitope bound by CR6261 on each of the various 
engineered proteins was measured by the ability of a given protein to compete the antibody CR6261 away from 
either substrate protein, in an ELISA, or pseudotyped virus, in a neutralization assay. Briefly, ELISA binding com-
petition was performed by incubating CR6261 with the competitor protein (H1 NC 99, H1 NC 99 Δstem, H1 NC 
99 SS, H1 NC 99 SS Δstem or gp120) at a concentration of 10 μg/ml prior to addition to plates pre-coated with 
H1 NC 99 (200 ng/well) and blocked with 5% skim milk21,22. Neutralization competition was performed as previ-
ously described21,25 in which serially diluted CR6261 (starting from 10 µg/mL) was incubated in the presence of a 
constant amount of H1 NC 99, H1 NC 99 SS, their respective Δstem Ile45Arg/Thr49Arg probes, or gp120 control 
(10 µg/mL) for 1 hr at RT before addition to pseudotyped recombinant HA/NA lentiviruses. The virus/antibody/
competitor mixture was then applied to 293 A cells, which where incubated overnight; media was changed after 
12–14 hours; and luciferase activity was measured 48 hours later as described21,25.
Human Sera Collection. In this study, we used archived serum samples that were collected from healthy 
adult donors (United States residents) between 2004 and 2010 in six Phase I vaccine clinical trials evaluating 
influenza, Ebola or SARS DNA vaccines. The samples were collected after approval from relevant institutional 
research ethics committees and using informed consent signed by the enrolled patients. The studies were 
conducted at the NIH Clinical Center by the NIAID Vaccine Research Center, National Institutes of Health 
(Bethesda, MD) (Clinicaltrials.gov identifiers: NCT00973895, NCT00489931, NCT00776711, NCT00099463, 
NCT01086657, NCT00072605). Sera samples assessed in this study were collected at baseline, prior to admin-
istration of any vaccine. All protocols were approved by the NIAID Intramural Institutional Review Board and 
U.S. Department of Health and Human Services human experimental guidelines for conducting clinical research 
were followed.
ELISA Binding and mAb competition assays. Human sera samples (n = 202) were first analyzed for 
their ability to bind SS probes from different subtypes (H1N1 A/New Caledonia/20/1999 (H1 NC 99) SS (sea-
sonal), H1N1 A/California/04/2009 (H1 CA 09) SS (pandemic), H2N2 A/Singapore/1/57 H2 (SING 57) SS, 
H5N1 A/Indonesia/5/2005 (H5 IND 05) SS, and H9N2 A/Hong Kong/1074/1999 (H9 HK 99) SS and their cor-
responding Δstem (Ile45Arg/Thr49Arg) mutants. Samples with binding end-point titers to WT SS, six-fold or 
higher than that to Δstem probe were considered positive for the presence of antibodies targeting broadly neu-
tralizing epitopes. Samples reactive to four out of five (4/5) probes were considered cross-reactive and were ana-
lyzed further by competition assay against F10-ScFv bNAb. Briefly, sera were diluted in blocking buffer (5% skim 
milk) containing constant amount (20 μg/ml) of competitor single-chain Fv (scFv) F10 or control anti-HIV scFv 
CH3126. Mixtures were then added to ELISA plates coated with H1 NC 99 SS (200 ng/well), incubated for 1 hr at 
RT, washed, and detected with anti-human Fc-specific secondary conjugated with HRP. Samples were considered 
positive for stem-epitope antibodies if they were competed by F10 but not by CH31 scFv with statistical signifi-
cance at 95% confidence interval using a two-tailed t-test.
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Cross-reactive B cells flow cytometry analysis. In order to assess HA- directed B cell binding and 
cross-reactivity, peripheral blood mononuclear cells (PBMC’s) from samples with different stem binding based 
on ELISA assay (n = 18) were further analyzed by flow cytometry. Three groups were selected for the analy-
sis: negative for stem antibodies (n = 5), reactive to one stem only (n = 4), and samples with cross-reactive 
stem binding (n = 9). Cryopreserved PBMC’s were thawed in R-10 media containing 50 U/mL of Universal 
Nuclease (ThermoFisher). Cells were washed and resuspended in PBS for staining with UV-Blue viability dye 
(ThermoFisher) for 20 minutes at room temperature. After washing, surface staining was performed using anti-
bodies against IgM (G20-127, BD Biosciences), IgG (G18-145, BD Biosciences), CD8 (RPA-T8, BioLegend), CD3 
(OKT3, BioLegend), CD56 (HCD56, BioLegend), CD14 (M5E2, BioLegend), CD19 (J3-119, Beckman Coulter), 
CD27 (O323, BioLegend), CD38 (HIT2, BioLegend), and HA probes27–29. H1 NC 99 and H5 INDO 05 HAs were 
expressed and biotinylated followed by fluorochrome labeling as previously described29. Stained cells were run on 
a BD LSRFortessa X-50 and data analysis was performed using FlowJo (TreeStar). The gating strategy is demon-
strated in supplemental Fig. 2. Statistical significance at 95% confidence interval was done using two-tailed t-test.
Neutralization assay. Cross-reactive samples (bound to 4/5 probes) based on ELISA assay were further 
assessed for neutralization of pseudotyped H1N1 NC 99 and H5N1 INDO 05 lentiviruses by neutralization com-
petition as previously reported21,25. Briefly, serially diluted serum samples (50- to 200- fold) were incubated with 
or without WT and Δstem HA competitor proteins at 10 µg/mL (H1 NC 99 in the case of H1N1 neutralization 
and H5 INDO 05 for H5N1 neutralization) for 1 hr at RT. Pseudovirus was added and the mixtures were incu-
bated for 30 min before applying them to 293 A cells. For certain sera samples that were found to neutralize virus 
pseudotyped with H1N1 NC 1999 in the presence of WT HA, the assay was repeated with serum preabsorbed 
with 293 F cells expressing the full-length (transmembrane) NC 99 Δstem protein, to remove head-dependent 
neutralization activity, as previously reported21,25. Samples were considered positive for stem dependent neutrali-
zation if the difference in neutralization competition between HA and HA Δstem was ≥20%.
Results
Characterization of HA Stabilized Stem Probes. To screen for antibodies targeting stem epitope of 
group 1 HA, we utilized a set of previously described12 HA SS probe constructs that lack the HA head domain 
while maintaining the stem region stabilized in the pre-fusion conformation (Fig. 1A,B). The probes were 
expressed as trimers (Supplemental Fig. 1) that preserved key structural elements as confirmed by crystal struc-
tures in complex with stem-specific monoclonal antibodies12. A version of the HA SS probe referred to as “Δstem” 
was also generated by introducing HA2 mutations I45R and T49R (H3 numbering) to block recognition of group 
1, HA stem-directed bNAbs.
The initial HA SS probe derived from H1 NC 99 HA bound two previously defined stem-directed bNAbs, 
CR6261 (Group1 HA specific24) and FI6v3 (Group1 and 2 HA6) with affinities similar to soluble HA trimers 
(Fig. 1C). The integrity of the SS probe was further confirmed by ELISA and neutralization competition assays. 
Similar to wild-type (WT) trimeric ectodomain HA, the HA SS probe competed CR6261 reactivity to H1 NC 99 
trimeric ectodomain HA (Fig. 1D) as well as CR6261 neutralization of an H1N1 NC 99 pseudovirus (Fig. 1E). 
In contrast, the Δstem version of HA and HA SS probes and the HIV gp120 control construct failed to inhibit 
CR6261 binding and neutralization activities.
Based on the same design as the H1 NC 99 HA SS probe, we generated four other probes representing pan-
demic H1 CA 09, H2 SING 57, H5 INDO 05, and H9 HK 99. The affinities of these probes for the CR6261 and 
FI6v3 were comparable to their respective HA ectodomains as determined by ELISA (Supplementary Table 1). 
For each, the respective Δstem mutant prevented binding by CR6261 (Fig. 1F).
Prevalence of Group 1 HA Stem Cross-Reactive Antibodies. Sera used in this study were collected 
at single time point from 202 random, healthy human subjects (20–65 years old) at single time points between 
November-2004 and May-2010. All sera samples were initially screened for HA stem antibodies by assessing their 
reactivity to WT HA SS versus Δstem HA SS probes (Fig. 2A). Samples with ELISA-endpoint titers 6-fold or 
greater to WT SS probes than to Δstem SS probes were considered positive for stem-epitope-specific antibodies. 
Using this criterion, 84% of the samples exhibited differential binding between WT and Δstem HA SS probes for 
at least one probe. About 60% of the samples had stem-epitope specific antibodies to H1 HA subtype probes (sea-
sonal or pandemic), and between 42% to 45% were reactive to non-circulating H2, H5 and H9 subtypes probes 
(Fig. 2A). When analyzed for reactivity breadth, 30% of the samples tested (60 out of 202) were cross-reactive to 
at least 4 of the 5 probes (Fig. 2B). Moreover, an ELISA competition assay showed that the binding of these same 
60 cross-reactive samples to the H1 HA SS probe was competed by F10-ScFv but not by the CH31-ScFv control 
antibody, confirming the presence of anti-stem epitope antibodies (Fig. 2C).
Frequency of Cross-Reactive Memory B Cells. To determine if the presence of cross-reactive 
stem-specific serum antibodies correlated with cross-reactive memory B cells, we evaluated memory B cell 
(CD19+CD38+CD27+IgG+IgM−) response in 18 peripheral blood mononuclear cells (PBMCs) samples by flow 
cytometry using two HA probes: H1 NC 99 and H5 INDO 05 (Supplementary Fig. 2). The mean frequency 
of cross-reactive H1+H5+ memory B cells was statistically higher in subjects whose sera reacted to at least 
four different HA SS probes in ELISA (average of 0.24%) than in subjects whose sera minimally reacted with 
only one (average of 0.084%) or zero (average of 0.083%) probes (p = 0.003, p = 0.001, respectively) (Fig. 3A). 
Furthermore, the frequency of H1+H5+ cross-reactive B cells was observed to correlate strongly with the relative 
magnitude of serum HA stem antibody binding (defined as the fold difference reactivity between WT and Δstem 
HA SS probes) (Fig. 3B).
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Figure 1. Design and characterization of HA SS protein. (A) Schematic of the HA SS (bottom) in comparison 
to HA (top). HA SS was constructed by inserting a GWG linker between residues 42 and 314 of HA1 (red) RBD 
head, a gp41 post-fusion trimerization motif (green) inserted in place of residues 59 through 93 of HA2 (blue), a 
GG linker between HA2 and the gp41 HR2 helix and an NGTGGGSG linker between the two gp41 helices. (B) 
Trimeric and monomeric representation of HA (PDB entry 1RU7) in comparison to the HA SS model. Coloring 
is respective to panel (A), with the monomeric representation also illustrating the CR6261 epitope as yellow and 
HA residues which are omitted in the stabilized HA stem as grey. (C) Binding of two bnAb, CR6261 and FI6v3, 
to WT and SS HA by ELISA. (D) Competition of CR6261 ELISA binding, and (E) pseudotyped neutralization 
with WT and Δstem (Ile54Arg/Thr49Arg HA2 mutations) HA and HA SS as competitors. HIV gp120 serves 
as a control. (F) CR6261 (10 µg/mL) ELISA reactivity to WT and ∆stem HA SS probes of different subtypes/
strains. H1 HA NC99 and HIV gp120 serve as controls. Error bars represent standard deviation of averaged 
points in each panel.
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Stem-Specific Neutralization of H1N1 and H5N1 Viruses. Next, we evaluated the neutralization 
breadth of the 60 broadly cross-reactive sera samples by measuring sera neutralization of H1N1 NC 99 and H5N1 
IND 05 pseudoviruses. The pseudotyped-lentivirus system was chosen due to its sensitivity, enabling the detec-
tion of neutralizing antibodies even at low titers. Samples were considered positive for stem dependent neutral-
ization if the difference in neutralization competition between HA and HA Δstem was ≥20%. (Supplementary 
Fig. 3). With these criteria, 47 out of 60 samples (78%) were positive for stem-epitope dependent neutralization 
of H1N1 pseudovirus (Fig. 4A). Thirty-three percent of cross-reactive samples had neutralizing activity to both 
subtypes, and only 5% were strictly H5N1 neutralizing (Fig. 4A). In total, one third of the samples designated 
as cross-reactive by ELISA had significant neutralization breadth against both H1N1 and H5N1 pseudoviruses 
that was dependent on HA stem epitope-reactive antibodies (Fig. 4A). H1N1 neutralization was independent of 
stem-directed antibody titers in the sera, as we saw no significant difference in ELISA endpoint titers between 
neutralizing and non-neutralizing samples (Fig. 4B). However, H5N1 neutralization correlated to antibody ELISA 
endpoint titer against the H5 INDO 05 HA SS probe (Fig. 4B).
Figure 2. Sera reactivity to HA SS probes. (A) Analysis of sera binding to WT HA SS versus ∆stem probes of 
H1 (seasonal and pandemic), H2, H5 and H9 subtypes. Samples are considered positive for the presence of 
stem-directed antibodies if endpoint titers between binding to WT and ∆stem probes are greater than 6-fold. 
Percentages of positive samples are indicated for each subtype. Error bars (red) correspond to standard Mean 
plus SD. (B) Cross-reactivity of sera to multiple SS probes. Percentage of samples that bound to 0–5 probe(s) is 
shown (n = 202). (C) Cross-reactive sera binding-competition with F10 ScFv. Sera that reacted with 4 out of 5 
probes (n = 60) were tested from stem specific antibodies in an ELISA with F10 ScFv as competitor. CH31 ScFv, 
HIV specific antibody, served as control.
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Determinants of Cross-Reactive Antibodies. Analysis of subjects’ traits and the presence of cross-reactive 
stem antibodies revealed no association with gender or race. Remarkably, sera collected either prior to the 
2009 pandemic or afterwards (after January 1, 201030–32) showed no differences in cross-reactivity or the abil-
ity to neutralize either H1N1 or H5N1 pseudovirus (Table 1). We also observed no difference in the profiles of 
cross-reactive sera from vaccinated and non-vaccinated samples collected after the H1N1 pandemic emergence 
(Table 1). However, there was a statistically significant boost in specific stem antibody titers to H1 CA 09 HA SS 
probe in subjects that received pandemic H1N1 influenza vaccine compared to those that did not receive the 
vaccine within the same time period (Fig. 5). We also noted a higher rate of cross-reactive antibodies in the older 
population, especially those born within or before the period of H2N2 pandemic33 (Table 1). While approxi-
mately 23% of the subjects less than 30 years of age were positive for cross-reactive antibodies, the percentage 
increased by 1.75- and 2.40-fold in subjects between the ages 40–49 and those over 50 years of age, respectively 
(Table 1). The higher rate of cross-reactive antibodies in the older population was consistent with the higher neu-
tralizing activity against of both H1N1 and H5N1 pseudoviruses. A 3–5-fold increase in H5N1 neutralization was 
noted in subjects between the ages 40–49 and those over 50, respectively, compared to those under the age of 30.
Discussion
An ideal influenza vaccine would trigger the immune system to recognize and target highly-conserved and vul-
nerable structures on the virus, such as the supersite for bNAbs on the HA stem domain34. Although several 
bNAbs that target this site have been isolated3–7, the profile of these antibodies in terms of their quality, quantity, 
specificity, and functionality in the general human population has not been thoroughly assessed. Here we pro-
vide a new serological approach for assessing the frequency, magnitude, breadth and specificity of antibodies in 
human sera directed to broadly neutralizing HA stem-epitope.
Figure 3. Correlation of IgG + memory B cells cross-reactivity and sera stem binding. (A) Frequencies of HA-
specific memory B cell populations in three sera stem-binding groups: negative for stem antibodies, reactive 
to one stem probe only, and cross-reactive sera which binds 4/5 stem probs. Error bars (red) correspond to 
standard mean plus SD. Groups were compared using unpaired t-test. (B) Correlation between frequency of 
cross-reactive B cells and relative sera binding (fold difference) to WT and Δstem probes.
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Figure 4. Stem-epitope dependent neutralization of H1N1 and H5N1 pseudoviruses. (A) Neutralization 
breadth of cross-reactive sera. Sera samples that bind to 4 or more HA SS probes were assayed for stem 
dependent neutralization of pseudotyped lentiviruses, H1 NC 99 and H5 IND 05, by neutralization competition 
assay. Samples with neutralization activity that is competed by WT but not Δstem HA is considered positive for 
stem directed nAb. The percentage of samples which neutralize H1 NC 99, H5 IND 05, both, or neither via the 
conserved stem epitope is shown. (B) Correspondence of sera neutralization activity to antibody titers. H1N1 
(left) and H5N1 (right) neutralizing and non-neutralizing samples corresponding to respective ELISA endpoint 
titers against HA SS probes. Error bars (red) correspond to standard Mean plus SD.
N
Subjects with Stem 
Cross-Reactivitya
Subjects with Stem Cross-Reactivity 
and H1 Stem Neutralization
Subjects with Stem Cross-Reactivity 
and H5 Stem Neutralization
Age
  <30 82 19 (23%) 13 (16%) 4 (05%)
  30–39 54 10 (19%) 8 (15%) 6 (11%)
  40–49 35 14 (40%) 12 (34%) 5 (14%)
  >50 31 17 (55%) 14 (45%) 8 (26%)
Date of Blood Draw
  Pre-2009 pandemic 79 18 (23%) 14 (18%) 6 (08%)
  Post-2010b 63 21 (33%) 21 (29%) 8 (13%)
Pandemic Vaccination (Post Pandemic Samplesc)
  Not Vaccinated 86 32 (37%) 25 (78%) 11 (34%)
  Vaccinated 38 9 (24%) 8 (89%) 5 (55%)
Table 1. Determinants of cross-reactive antibodies. aSamples considered to have HA stem cross-reactivity had 
at least a 6-fold differential binding between HA SS wt and Δstem probes for 4 of 5 probes. bSamples collected 
after the second massive wave of the 2009 pandemic (starting from January 1st, 2010). cSamples collected after 
the initial diagnosis of pandemic cases on April 14th, 2009.
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Our analyses improve upon other published papers8,14–20 in that we analyzed higher number of samples, we 
used structurally defined stem-only HA SS probes to detect stem-directed antibodies paired with Δstem probes 
to confirm the epitope targeted, and we assayed antibody binding and neutralizing breadth on individual serum 
samples, rather than pooled sera. The HA SS probes allow definitive measurement of stem antibodies without 
the potential interference of anti-HA head antibodies, while Δstem probes measure and allow us to account for 
antibodies targeting the specific epitope encompassing the supersite for bNAbs. Furthermore, by utilizing HA 
SS probes for several HA subtypes (seasonal and pandemic H1, H2, H5, and H9) we were able to directly assess 
the breadth of sera reactivity to all four group 1 HA subtypes known to have infected humans. In addition, we 
demonstrated a correlation between HA stem-specific antibody binding and neutralization with the presence of 
cross-reactive HA-specific B cells that have been shown in other studies to express immunoglobulins that target 
the HA stem27,34.
Analyses of sera samples with HA SS probes indicated wide prevalence of stem antibodies, as only 16% of 
subjects lacked bNAb-epitope-specific reactivity. As expected, reactivity to the H1 HA subtypes, both seasonal 
and pandemic, was commonly observed (~60%). However, 42%–45% of samples also reacted to the stem-epitope 
of the non-circulating subtypes (H2, H5, and H9). Furthermore, 30% (n = 60) of the samples harbored reactivity 
to at least 4 out of 5 probes. Our findings suggest a much higher prevalence of group 1 HA stem epitope directed 
antibodies in the general population (84%) than previously reported values of up to 30% in unvaccinated sub-
jects14. BNAbs recognizing group 1 HA stem have been shown to arise predominantly (>60 %) from the IGHV1-
69 v-gene28,29. Moreover, antibodies containing the VH1-69 v-gene have been observed to be expressed at high 
levels of up to 11%35. Finally, germline-reverted, VH1-69-containing, HA stem-reactive bNAbs have been shown 
to recognize group 1 HA stem antigens and require minimal levels of somatic hypermutation for maturation11. 
Therefore, the human immune system has evolved the capacity to generate stem-directed influenza antibodies in 
the large majority of individuals. The difference in the reported seroprevalence rate of stem-directed antibodies 
in this study compared to others could be referred to the difference in the used methodology and type of analysis. 
Firstly, we used multiple subtypes to screen for stem antibodies, which enables better detection coverage, and sec-
ondly, we specifically screened for epitope-specific response by utilizing WT and Δstem probes, while defining a 
cutoff value of end-point-binding-titer fold difference between the two probes.
We also tested whether the 60 most cross-reactive samples could neutralize virus. Most neutralized 
H1N1-pseudotyped virus, and more than a third neutralized H5N1-pseudotyped virus, despite no previous 
exposure to this subtype. Neutralizing activity against H5N1, but not H1N1 virus, correlated with the magnitude 
of serum antibody binding, indicating a possible correlation between antibody level in sera and the potential for 
heterosubtypic immunity. Variation in the ability of stem antibodies to achieve heterosubtypic neutralization 
might also rely on maturation pathways of specific antibody lineages and the exposure history to prior infections 
or vaccinations34.
Because our primary interest was to understand the underlying factors leading to the elicitation of bNAb, we ana-
lyzed the traits of subjects possessing cross-reactive sera capable of recognizing at least four of the subtypes tested. 
We found that the incidence of cross-reactive antibodies, as well as their neutralizing activity of H1N1 and H5N1 
pseudoviruses, was age dependent. This could be due to a more extensive exposure to diverse influenza strains via 
infection or vaccination. This includes the exposure to H2N2 subtype that circulated between 1957 and 196833, 
as well as the swine H1N1 strain that emerged in the late 1970s36. Moreover, childhood imprinting by the first 
Figure 5. Correspondence between pandemic H1N1 exposure and anti-HA stem antibody titer in human sera. 
Reactivity to CA 09 HA SS of serum samples collected before and after (vaccinated and unvaccinated) the 2009 
H1N1 pandemic. Error bars (red) correspond to standard Mean plus SD.
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influenza strains encountered by a subject has been suggested to play a role in adult immune response to influ-
enza37. The breadth of antibody binding in sera correlated with the frequency of cross-reactive memory B cells 
isolated from PBMCs. These observations support the possibility that long-lived memory B cells targeting this 
conserved site exist15 and could potentially be boosted by vaccines designed to display HA stem epitopes.
Consistent with previous reports8,15,38, we also observed an increase in stem-directed antibodies specific for 
the pandemic H1 HA in individuals vaccinated for that strain. This observation supports the hypothesis suggested 
by others that an HA molecule with a novel head domain presented with an HA stem domain from a previous 
exposure may be able to boost cross-reactive HA stem-specific antibody responses39,40. However, we observed 
no difference in the prevalence of cross-reactive antibodies in samples collected before the 2009 pandemic, and 
those collected after January 1st of 2010 (after the second wave of infection in which a substantial percentage of the 
population is thought to have encountered the virus by infection or vaccination)30–32. Clearly, many people might 
not have been exposed to the virus after the second wave, whether by vaccination or infection, which partially 
explain our results.
Although we were looking for epitope-specific antibodies by utilizing WT and Δstem probes, our data suggest 
that some HA stem-specific antibodies could be subtype specific, as denoted by the lower frequency of antibody 
binding to non-circulating subtypes (H2, H5, and H9) compared to circulating subtypes (seasonal and pandemic 
H1). Furthermore, although significant number of sera samples were broadly reactive in terms of stem binding 
as measured with ELISA, only a subset of these (30%) were able to neutralize a divergent non-circulating group 1 
virus (H5N1). These observations suggest that subtle variations in the specificity of stem-directed antibodies or 
structures of HA stem surfaces between subtypes may result in varying degrees of breadth. Our resluts also indi-
cate that these antibodies could be cross-reactive but not necessarily cross-neutralizing, partially depending on 
their titers in the sera. Whether such cross-reactivity translates into other effector mechanisms such as ADCC and 
CDC requires further investigations. Importantly, these observations suggest that HA stem-based vaccination 
strategy might require the use of multiple components to provide broader protection, especially when it comes to 
cross-group neutralization such as H3 and H7.
Overall, this emphasizes the importance of evaluating reactivity against multiple HA stem subtypes to gauge 
the breadth of antibody cross-reactivity, especially when evaluating the immunogenicity of candidate universal 
influenza vaccines. It is worth noting here that stem-directed antibodies could provide protection against het-
erosubtypic pathogenic viruses regardless of the neutralization activity as we reported earlier in mouse and feret 
models12. This mandates the development of additional procedures to measure other activities of stem-directed 
antibodies, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-mediated 
complement-dependent cytotoxicity (CDC).
Our results and those of others14,15 leave several questions unanswered: why do we need annual vaccina-
tion to protect from influenza infection if stem-directed antibodies are prevalent, what is the minimal titer of 
HA stem-specific antibody required for immunity against influenza disease, would the effectiveness of HA 
stem-specific antibody differ in upper versus lower respiratory tract infection, will an HA stem-based vaccine 
antigen provide immunity against strains within a subtype, across subtypes within a group, or across groups of 
influenza A?
It is worth noting that ADCC and CDC would be more prominent in the lung due to the availability of effector 
cells in such environment, while most of the circulating influenza viruses tend to cause upper respiratory tract 
infection (URTI). On the other hand, H5N1 viruses are known to cause lower respiratory tract infections (LRTI) 
in humans. Interestingly, a meta-analysis of studies that evaluated the serological evidence of H5N1 infections 
in humans indicated a seropositivity up to 2% in high risk groups and concluded that H5N1 viruses can cause 
mild or subclinical infections in humans41. Our findings in animal models indicate that stem antibodies can pro-
tect against lethal H5N1 infection although they lack measurable neutralizing activity against the virus in vitro, 
which suggest the involvement of other mechanisms such as ADCC and CDC. This suggest that stem antibodies 
might provide better protection from LRTI rather than URTI. Evaluating anti-stem antibodies in passive transfer 
experiments in human challenge studies to define whether neutralization or Fc-mediated effector functions were 
required for protection would be highly informative.
In summary, we developed an important tool for measuring stem-directed antibodies in human sera and 
illustrated how these assays will inform vaccine development. Our analyses indicates that stem-directed anti-
bodies are prevalent in human sera across age groups, although the breadth and function of antibody’s binding 
and neutralization can be dependent on age and presumably the exposure history. Therefore, it may be feasible 
to design candidate vaccines that can effectively boost pre-existing responses with cross-protective capacity. Our 
analysis also shows that not all stem-directed antibodies in human sera are equally broad. Therefore, universal 
influenza vaccine candidates will need to be designed to activate selected precursors and may require more than 
one component to generate the desired breadth of protection.
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